A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, University of California, San Francisco, The University of Texas Health Science Center at Houston, Rush University Medical Center, Women's Cancer Center of Nevada, Washington University in St. Louis, University of California, Irvine, University of California, Irvine Medical Center, Abington Memorial Hospital, Gynecologic Oncology Group
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891849475